9-Oct-2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:01 PM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Mon, 21-Sep 9:00 AM ET)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Globe Newswire (Wed, 26-Aug 8:00 AM ET)
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
Globe Newswire (Wed, 29-Jul 8:00 AM ET)
Globe Newswire (Fri, 24-Jul 8:00 AM ET)
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Globe Newswire (Wed, 15-Jul 8:30 AM ET)
Market Chameleon (Mon, 6-Jul 4:36 AM ET)
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Newamsterdam Pharma Company N.V. - trades on the NASDAQ stock market under the symbol NAMS.
As of October 9, 2026, NAMS stock price climbed to $21.58 with 1,170,966 million shares trading.
NAMS has a beta of 0.90, meaning it tends to be less sensitive to market movements. NAMS has a correlation of 0.03 to the broad based SPY ETF.
NAMS has a market cap of $2.58 billion. This is considered a Mid Cap stock.
Last quarter Newamsterdam Pharma Company N.V. - reported $4 million in Revenue and -$.52 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.09.
In the last 3 years, NAMS traded as high as $42.21 and as low as $5.63.
The top ETF exchange traded funds that NAMS belongs to (by Net Assets): CGMM, IBB, VHT, SBIO, ESML.
NAMS has underperformed the market in the last year with a price return of -34.6% while the SPY ETF gained +17.1%. NAMS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.9% and -4.5%, respectively, while the SPY returned +3.8% and +0.9%, respectively.
NAMS support price is $20.46 and resistance is $22.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NAMS shares will trade within this expected range on the day.
